Levodopa+carbidopa Fair-Med (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier and is converted into dopamine within the central nervous system. This increase in dopamine helps compensate for the loss of dopaminergic neurons characteristic of Parkinsonian disorders.

The dose of levodopa/carbidopa is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made during follow‑up visits to achieve optimal symptom control while minimizing side effects.

Safety data for levodopa/carbidopa in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levodopa/carbidopa is considered the most effective symptomatic therapy for Parkinson's disease, especially for motor control. Compared with dopamine agonists or MAO‑B inhibitors, it often provides greater symptom relief but may have a higher incidence of motor complications such as dyskinesia.

Store the oral tablets at room temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Levodopa+carbidopa Fair-Med is taken orally, usually with a small amount of food to reduce gastrointestinal irritation. Tablets should be swallowed whole with water and not crushed or chewed unless specifically directed by a healthcare professional.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, and rare but life‑threatening allergic reactions. Patients should be monitored regularly for these complications.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors and in those with narrow‑angle glaucoma or malignant melanoma without careful risk assessment.